To include your compound in the COVID-19 Resource Center, submit it here.

Rituxan rituximab: Pilot data; Phase II; marketed to treat low-grade non-Hodgkin's lymphoma (NHL)

In a 1-year study of 5 RA patients who had failed treatment with at least 5

Read the full 161 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE